Compare Summit Therapeutics Inc (SMMT) vs State Street Technology Select Sector SPDR ETF (XLK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs State Street Technology Select Sector SPDR ETF — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while State Street Technology Select Sector SPDR ETF trades at $180.42. The key difference: State Street Technology Select Sector SPDR ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | XLK | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | Sector/Thematic |
52-Week High | $29.32 | $198.21 |
52-Week Low | $13.05 | $127.49 |
Enterprise Value | $9.90B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.
The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.
XLK, the Technology Select Sector SPDR Fund, trades at $175.71 with a slight 0.07% daily gain. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators are neutral. The fund has delivered strong year-to-date performance, up 33% as of July 2, 2026 (ETF Trends), but faces concentration risks in mega-cap tech holdings. Recent news highlights ongoing institutional interest in tech ETFs amid robust earnings expectations for the sector.
The outlook for XLK remains tied to technology sector strength, with Q2 earnings expected to show 23.3% growth for the S&P 500 (ETF Trends, July 13, 2026). Key risks include sector concentration and market volatility. Wall Street sentiment is positive due to strong fundamentals, but investors should monitor earnings results and Fed policy impacts on growth stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About State Street Technology Select Sector SPDR ETF
XLK tracks the Technology Select Sector Index, providing targeted exposure to the largest and most influential technology companies within the S&P 500. It is a highly concentrated, liquid vehicle focused on software, semiconductors, and hardware leaders, serving as the primary benchmark for U.S. large-cap technology performance.
Read more on XLK →
